Zobrazeno 1 - 10
of 1 358
pro vyhledávání: '"Ortonne Jp"'
Autor:
Fanian F, Mac-Mary S, Jeudy A, Lihoreau T, Messikh R, Ortonne JP, Sainthillier JM, Elkhyat A, Guichard A, Hejazi Kenari K, Humbert P
Publikováno v:
Clinical Interventions in Aging, Vol Volume 8, Pp 1527-1537 (2013)
Ferial Fanian,1,2 Sophie Mac-Mary,3 Adeline Jeudy,1,2 Thomas Lihoreau,1,2 Rafat Messikh,1,2 Jean-Paul Ortonne,4 Jean-Marie Sainthillier,3 Ahmed Elkhyat,1,2 Alexandre Guichard,1,2 Kamran Hejazi Kenari,1,2 Philippe Humbert1,2,5,61Center for Studies and
Externí odkaz:
https://doaj.org/article/18ed0fe793174c47870644e02e74f3e7
Autor:
Benedetto JP, Ortonne JP
Publikováno v:
Genetics Selection Evolution, Vol 13, Iss 1, Pp 17-26 (1981)
Externí odkaz:
https://doaj.org/article/284cd7fe403a4f6584e41551c02790cc
Autor:
Stephanie Nouveau, Christine Duval, V. Piffaut, O. de Lacharrière, Philippe Bastien, Emilie Warrick, Françoise Bernerd, B. Chalmond, Ortonne Jp
Publikováno v:
British Journal of Dermatology. 177:1619-1632
Background Actinic lentigos (AL) are benign hyperpigmented skin lesions associated with photoageing. Despite their high prevalence, biological mechanisms driving their formation remain unclear. Objectives To provide new insights about the physiopatho
Autor:
S.Y. Chuah, K. Tsilika, Jean-Philippe Lacour, Christine Chiaverini, E. Fontas, Ortonne Jp, Philippe Bahadoran
Publikováno v:
British Journal of Dermatology. 172:88-93
Summary Background Acral naevi are a peculiar subtype of naevus with specific dermoscopic patterns. Little is known about congenital melanocytic naevi affecting acral volar skin in children. Objectives To determine the dermoscopic features of acquire
Autor:
V. Frangione, A. Grodzińska, Luigi Naldi, Sergio Chimenti, M. Esposito, M. Kapińska‐Mrowiecka, Ortonne Jp
Publikováno v:
Journal of the European Academy of Dermatology and Venereology
Background A ready-to-use betamethasone valerate 0.1% (BMV) dressing was found to be superior to placebo dressing and a reference 0.1% BMV cream in the treatment of patients with chronic plaque psoriasis (CPP). Methods This multicentre, prospective,
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 28:374-377
Background Blanching creams are used to depigment and to achieve uniform skin tone in widespread vitiligo.Length of the treatment and side-effects strongly limit their use in common practice.Objectives To assess the long-term efficacy and tolerance
Autor:
Kristian Reich, Alice B. Gottlieb, I.J. Terpstra, G. Coteur, C. Tasset, Ortonne Jp, P. J. Mease
Publikováno v:
British Journal of Dermatology. 167:180-190
Summary Background Certolizumab pegol (CZP) is a PEGylated antitumour necrosis factor agent. Objectives To evaluate the efficacy and safety of CZP in patients with plaque psoriasis. Methods In a randomized, placebo-controlled, double-blind study, 176
Autor:
Ortonne Jp, Philippe Bahadoran, Jean-Philippe Lacour, F. Le Duff, L. Sillard, Thierry Passeron, W. Bayoumi, E. Fontas
Publikováno v:
British Journal of Dermatology. 166:208-211
Summary Background The treatment of vitiligo remains unsatisfactory. Objectives To assess in patients with vitiligo the effect of a laser dermabrasion in addition to the association of topical steroids and ultraviolet (UV) B in difficult-to-treat are
Autor:
Kristian Reich, Hanzhe Zheng, Ortonne Jp, H. J. F. van Hoogstraten, Jonathan Barker, Gottfried Wozel, Maurice Hoffmann
Publikováno v:
British Journal of Dermatology. 165:1109-1117
Summary Background Infliximab is indicated for treatment of moderate-to-severe plaque psoriasis in adults whose disease cannot be controlled with other systemic therapies, including methotrexate (MTX). To date, no studies have directly compared the e
Autor:
Fenouille N, Mélanie Tichet, Stéphane Rocchi, Zimniak G, Marcel Deckert, Patricia Abbe, Sophie Tartare-Deckert, Alexandre Puissant, Ortonne Jp, Aude Mallavialle, Robert Ballotti
Publikováno v:
Oncogene. 30:4887-4900
Aberrant expression of Secreted Protein Acidic and Rich in Cysteine (SPARC)/osteonectin has been associated with an invasive tumor cell phenotype and poor outcome in human melanomas. Although it is known that SPARC controls melanoma tumorigenesis, th